Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Richard S. Finn; Masatoshi Kudo; Gisoo Barnes; Tim Meyer; Frédéric Boisserie; Ramil Abdrashitov; Yaxi Chen; Songzi Li; Andrew X. Zhu; Shukui Qin; Arndt Vogel

doi:10.1159/000537966

Abstract

1 min read

Patients with 1L HCC treated with tislelizumab had favorable HRQOL outcomes compared with patients treated with sorafenib, particularly in fatigue and physical functioning. These results, along with favorable safety profile, better response rate, and OS noninferiority, support tislelizumab as a potential 1L treatment option for unresectable HCC.

Related publications

Article2023

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn, Shukui Qin, Masatoshi Kudo, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Gisoo Barnes, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel

Article2023

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn, Shukui Qin, Masatoshi Kudo, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Gisoo Barnes, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel

Article2019

RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Richard S. Finn, Masatoshi Kudo, Tim Meyer, Arndt Vogel, Michel Ducreux, Teresa Macarulla, Gianluca Tomasello, Frédéric Boisserie, Jeannie Hou, Xin Li, James Song, Andrew X. Zhu

Article2025

Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

Masatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, Tatsuya Yamashita, Masayuki Kurosaki, Tadashi Namisaki, Shuhei Hige, Yoshito Itoh, Satoshi Mochida, Tetsuya Hosaka, Norio Akuta, Tomokazu Kawaoka, Takuya Genda, Satoshi Kobayashi, Sawako Uchida‐Kobayashi, Yuting Lu, T Ogata, Maria Jesus Jimenez Exposito, Masafumi Ikeda

Article2023

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Masatoshi Kudo, Richard S. Finn, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel, Shukui Qin

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Abstract

Discussion(0)

Related publications

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).